Cytokinetics Logo
US23282W6057
A1W1KK
CYTK

Cytokinetics

Prévisions

L'objectif de cours moyen des analystes est de 97,64 € (+110,89 %). La médiane est de 102,07 € (+120,45 %).

Acheter
  34
Conserver
  1
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Cytokinetics added to Polaris portfolio after Myqorzo seen superior to Camzyos

    Polaris Capital Management added Cytokinetics to its Q2 2026 Global Equity Strategy, citing FDA approval of Myqorzo for hypertrophic cardiomyopathy and its perceived superiority to Bristol Myers Squibb's Camzyos in symptom relief and dosing simplicity. Cytokinetics closed at $67.59 on Sept. 22, 2026, with a market cap of $9.4 billion, a 52-week range of $47.22–$88.31 and a one-month decline of 14.66% versus a 52-week gain of 39.97%. Polaris noted the company amid strong quarter-wide gains driven by AI holdings, and hedge fund ownership of Cytokinetics rose to 78 portfolios at quarter end. » Plus sur finance.yahoo.com


  • Cytokinetics bets on MYQORZO expansion in HCM and prepares NHCM approval

    At the Citigroup conference, Cytokinetics reported a better-than-expected launch for MYQORZO in obstructive HCM, capturing a 40% share of new prescriptions by the end of Q2 2026. ACACIA-HCM phase 3 data showed superiority in non-obstructive HCM (NHCM) and support a planned regulatory filing; the company estimates NHCM could represent about 50% of the HCM market. There was a slight imbalance of serious heart-failure events in ACACIA, which the company views as manageable and plans to publish additional safety data. Cytokinetics plans to increase SG&A spending to support NHCM expansion and its European roll‑out (Germany launched, UK Q4 2026, other markets in 2027) and is advancing the COMET-HF confirmatory study of Omecamtiv Mecarbil in parallel. » Plus sur de.investing.com


  • Cytokinetics beats Q2 2026 estimates thanks to launch of MYQORZO

    Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Plus sur de.investing.com


  • MHRA grants Cytokinetics approval for Aficamten in the UK

    The MHRA has approved Cytokinetics’ Aficamten (MYQORZO) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. NICE recommends use in England and Wales for patients in NYHA classes II–III as an add‑on to optimized standard therapy or as monotherapy when there are contraindications. The decision is based on the phase‑3 SEQUOIA‑HCM study, which showed a mean difference in peak oxygen uptake of 1.7 ml/kg/min (p < 0.001) versus placebo. Common adverse events included hypertension, palpitations, dizziness and systolic dysfunction; availability through the NHS is expected later this year. » Plus sur de.investing.com


  • Cytokinetics gains momentum as Myqorzo commercial rollout expands

    Cytokinetics is transitioning from development to commercial stage following regulatory approvals for Myqorzo in the US, Europe and China, with early physician adoption and patient response supporting initial sales momentum. Positive trial readouts are expanding the drug's potential into related cardiac indications, while a differentiated mechanism and a pipeline of next-generation candidates could broaden its addressable market. Market interest and volume-supported price action indicate accumulation as investors reassess long-term growth and pricing power in a market with limited competition. » Plus sur finance.yahoo.com

Données financières

Au dernier trimestre, Cytokinetics a réalisé un chiffre d'affaires de 41,99 M € et un bénéfice net de -167,8 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 41,99 M 2 445,01 %
Bénéfice brut 40,03 M 2 326,43 %
Bénéfice net -167,8 M 35,68 %
EBITDA -130,61 M 44,70 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
6,52 Md €
Nombre d'actions
139,3 M
Plus haut/bas sur 52 semaines
80,48 € - 46,52 €
Dividendes Non
Bêta
0,36
Ratio P/E
-8,51
Ratio PEG
-8,41
Ratio P/B
-22,22
Ratio P/S
63,10

Profil de l'entreprise

Cytokinetics, Incorporated, une société biopharmaceutique en phase avancée de développement, se consacre à la découverte, au développement et à la commercialisation d'activateurs et d'inhibiteurs musculaires comme traitements potentiels de maladies invalidantes. La société développe des candidats médicaments à petites molécules conçus principalement pour agir sur la fonction et la contractilité musculaires. Ses candidats médicaments comprennent l'omecamtiv mecarbil, un nouvel activateur de la myosine cardiaque en essai clinique de phase III chez des patients souffrant d'insuffisance cardiaque ; et le reldesemtiv, un activateur de la troponine du muscle squelettique, en essai clinique de phase III pour le traitement de la sclérose latérale amyotrophique et de l'amyotrophie spinale. La société développe également le CK-136, un nouvel activateur de la troponine cardiaque en essai clinique de phase I ; l'aficamten, un nouvel inhibiteur de la myosine cardiaque, en essai clinique de phase III pour le traitement de patients atteints de cardiomyopathie hypertrophique obstructive symptomatique ; et le CK-3772271, un inhibiteur de la myosine cardiaque à petites molécules en essai clinique de phase I. Cytokinetics, Incorporated a conclu une alliance stratégique avec Astellas Pharma Inc. La société a été constituée en 1997 et son siège social se situe à South San Francisco, en Californie.

Nom
Cytokinetics
PDG
Robert I. Blum
Siège social South San Francisco, ca
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
30/04/2004
Employés 673

Symboles boursiers

Bourse Symbole
NASDAQ
CYTK
Frankfurt
KK3A.F
Düsseldorf
KK3A.DU
SIX
KK3A.SW
München
KK3A.MU
🍪

Parqet  utilise des cookies. En savoir plus